Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
0.54 (1y: +17%)
Market Cap 92.6 M P/E(ttm)
Enterprise Value P/B 2.70
NBS- (USA)
Neostem Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$0.54
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash to Debt 1.5
NBS's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NBS: 1.5 )
NBS' s 10-Year Cash to Debt Range
Min: 0   Max: 0
Current: 1.5
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Revenue Growth (%) 201.8
NBS's Revenue Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NBS: 201.8 )
NBS' s 10-Year Revenue Growth (%) Range
Min: -42.8   Max: 201.8
Current: 201.8
-42.8
201.8
EBITDA Growth (%) -23.8
NBS's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NBS: -23.8 )
NBS' s 10-Year EBITDA Growth (%) Range
Min: -45.9   Max: -3.8
Current: -23.8
-45.9
-3.8
EPS Growth (%) -22.9
NBS's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NBS: -22.9 )
NBS' s 10-Year EPS Growth (%) Range
Min: -38.3   Max: -3.1
Current: -22.9
-38.3
-3.1
» NBS's 10-Y Financials

Financials


» Details

Insider Trades

Latest Guru Trades with NBS



No Insider Trades Found!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/B 2.70
NBS's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NBS: 2.70 )
NBS' s 10-Year P/B Range
Min: 0   Max: 2.7
Current: 2.7
0
2.7
P/S 5.50
NBS's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NBS: 5.50 )
NBS' s 10-Year P/S Range
Min: 0   Max: 5.5
Current: 5.5
0
5.5
EV-to-EBIT 1
NBS's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NBS: 1 )
NBS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 1
PEG 1.1
NBS's PEG is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NBS: 1.1 )
NBS' s 10-Year PEG Range
Min: 0   Max: 1.3
Current: 1.1
0
1.3

Valuation & Return

vs
industry		 vs
history
Price/Tangible Book 2.7
NBS's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NBS: 2.7 )
NBS' s 10-Year Price/Tangible Book Range
Min: 0   Max: 0
Current: 2.7
Earnings Yield (Greenblatt) 102.50
NBS's Earnings Yield (Greenblatt) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NBS: 102.50 )
NBS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 110.7
Current: 102.5
0
110.7

Business Description

Neostem, Inc. was incorporated under the laws of the State of Delaware in September 1980 under the name Fidelity Medical Services, Inc. It is an international biopharmaceutical company. It operates in three reportable segments: (i) Cell Therapy-United States; (ii) Regenerative Medicine-China; (iii) Pharmaceutical Manufacturing-Manufacturing. It is pursuing the divestiture of the majority of its China operations and anticipates they will have been exited by the close of 2012. Through the Cell Therapy- United States segment, it is focused on the development of proprietary cellular therapies in cardiovascular disease, immunology and regenerative medicine and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science. Within this segment, it also provides adult stem cell collection, processing and storage services in the U.S., enabling healthy individuals to donate and store their stem cells for personal therapeutic use. In addition, the Company collects and stores cord blood cells of newborns which help to ensure a supply of autologous stem cells for the child should they be needed for future medical treatment. Through its Regenerative Medicine- China segment, in 2009, it began several China-based, Regenerative Medicine initiatives including: (i) constructing a stem cell research and development laboratory and processing facility in Beijing, (ii) establishing relationships with hospitals to provide cell-based therapies, and (iii) obtaining product licenses covering several adult stem cell therapeutics focused on regenerative medicine. As a result of certain changes in the PRC regulatory environment, the Company has determined to take steps to restrict, and expects to ultimately eliminate, its Regenerative Medicine business in the PRC.
Company Website
Industry:
Compare:
Traded in other countries:XIU.Canada
» More Articles for :NBS

Headlines

Articles On GuruFocus.com
3 Best Yielding Stocks Which Hit Recently All-Time-Highs Jun 19 2013 
Is This Fast Food Giant A Safe Bet? Jun 19 2013 
Is This Fast Food Giant A Safe Bet? Jun 19 2013 
Royalty. Pure play i Jun 18 2013 
Whitney Tilson Lecture at Darden - An introduction to Value investing Jun 18 2013 
comment on EMC Jun 18 2013 
Brian Rogers' Stock Picks for Barron's Midyear Roundtable Jun 18 2013 
comment on WU Jun 18 2013 
Top Stocks of John Paulson’s Real Estate Recovery Fund, Up 27% Jun 18 2013 
Chicago Bridge & Iron, A Buy? Jun 18 2013 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK